Instylla is a privately held company focused on developing peripheral liquid embolic products based on its proprietary hydrogel technology to improve patient outcomes, procedure efficiency, and enable new therapies. The company was founded by Incept LLC in 2017 and is funded by several leading venture capital groups and Instylla principals.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/15/20 | $25,400,000 | Series B |
AMED Ventures Ascension Ventures Catalyst Health Ventures Excelestar Ventures Sparta Group | undisclosed |
